NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome (LYNCH-CHROMO)
Comparison of Colonoscopy With Virtual Chromoendoscopy Using 3rd Generation NBI System to Chromoendoscopy With Indigo Carmine in Lynch Patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- AP-HP - hôpital européen Georges-Pompidou
-
-
Auvergne-Rhône-Alpes
-
Lyon, Auvergne-Rhône-Alpes, France, 69003
- HCL - Hôpital Edouard-Herriot
-
-
Centre-Val De Loire
-
Chambray-lès-Tours, Centre-Val De Loire, France, 37170
- CHRU de Tours - Hôpital Trousseau
-
-
Pays De La Loire
-
Nantes, Pays De La Loire, France, 44093
- CHU Nantes - Hôtel-Dieu
-
-
Île-de-France
-
Paris, Île-de-France, France, 75014
- AP-HP - Hôpital Cochin
-
Paris, Île-de-France, France, 75012
- AP-HP - hôpital Saint-Antoine
-
Villejuif, Île-de-France, France, 94805
- Institut Gustave-Roussy
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Lynch Syndrome with an identified mutation in one of the genes MutL Homolog 1 (MLH1), MutL Homolog 2 (MLH2), MutS homolog6 (MSH6), PMS2 or epithelial cellular adhesion molecule (EpCAM)
- Age between 18 and 80
- Indication of a screening colonoscopy
Exclusion Criteria:
- Any sign of intestinal occlusion contra-indicating bowel preparation
- History of total or subtotal colectomy
- Any serious medical condition contra-indicating colonoscopy under general anesthesia
- Pregnant or breast feeding women
- Any coagulation disorder contra-indicating biopsies or endoscopic resections
- Any history of hypersensitivity to indigo carmine
- Adults subject to a legal protection measure (guardianship or curatorship)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Indigo carmine colonoscopy
Colonoscopy using indigo carmine is performed in second place
|
A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
|
|
Experimental: NBI colonoscopy
Colonoscopy using NBI is performed in first place
|
A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of adenomas and / or adenocarcinoma detected during each procedure (NBI vs Indigo carmine)
Time Frame: procedure time
|
The adenoma detection rate (number of adenoma and/or adenocarcinoma) of NBI and the additional adenoma detection rate of indigo carmine.
|
procedure time
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All neoplastic lesions detected during colonoscopy
Time Frame: procedure time
|
Collect the number, size, location, endoscopic (Paris Classification) and anatomo-pathologic aspect (adenoma, hyperplastic polyp, adenocarcinoma) of all detected lesions with their respective prevalence.
|
procedure time
|
|
Cost of each procedure (NBI vs Indigo carmine)
Time Frame: Procedure time
|
Evaluate the cost of each procedure including therapy.
|
Procedure time
|
|
Duration of each procedure (NBI vs Indigo carmine)
Time Frame: Procedure time
|
Evaluate the duration of each procedure (with and without endoscopic therapy).
|
Procedure time
|
|
Number of subject with adverse events as mesure of safety.
Time Frame: One month after colonoscopy
|
Followed a month post colonoscopy to evaluate the occurrence of undesirable events
|
One month after colonoscopy
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: CHRISTOPHE CELLIER, MD, PHD, Hôpital Europeén Georges Pompidou
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Metabolic Diseases
- Neoplasms
- Neoplasms by Site
- Disease
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Colorectal Neoplasms
- Neoplastic Syndromes, Hereditary
- DNA Repair-Deficiency Disorders
- Syndrome
- Colorectal Neoplasms, Hereditary Nonpolyposis
Other Study ID Numbers
Other Study ID Numbers
- P140108
- 2015-A00552-47 (Other Grant/Funding Number: ANSM)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.